--- title: "Cocrystal Pharma (COCP) news: offering" url: "https://aibio.space/companies/cocrystal-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "COCP offering news: Cocrystal sells $5 million of stock to OPKO Health. Cocrystal Pharma, Inc. (NASDAQ: COCP), United States." --- COCP Cocrystal Pharma, Inc. NASDAQ · United States # Cocrystal Pharma (COCP) news COCP offering news Company Updates · 2026-09-09 ## [Cocrystal doses last subject in CDI-988 norovirus challenge study](https://aibio.space/news/cocrystal-doses-last-subject-cdi-988-norovirus-challenge-study/) Cocrystal Pharma said on September 9, 2026 that it dosed the last subject in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected in late 2026 or early 2027. ## Latest Cocrystal Pharma news 1. 2026-08-18 Company Updates [Cocrystal appoints Carol L. Brosgart to its board of directors](https://aibio.space/news/cocrystal-appoints-carol-l-brosgart-board-directors/) Cocrystal Pharma's board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately, according to a Form 8-K filed August 18, 2026. 2. 2026-08-03 Financings [Cocrystal sells $5 million of stock to OPKO Health](https://aibio.space/news/cocrystal-sells-5-million-stock-opko-health/) OPKO Health, a longtime shareholder, buys 5,474,053 shares at $0.9134 each in a private placement with no warrants attached. 3. 2026-06-09 Company Updates [Cocrystal names James Sapirstein chief executive officer](https://aibio.space/news/cocrystal-names-james-sapirstein-chief-executive-officer/) An 8-K filed June 9, 2026 sets out the offer letter for the new chief executive, who replaces two co-chief executives. 4. 2026-06-03 Company Updates [Cocrystal appoints James Sapirstein as chief executive officer](https://aibio.space/news/cocrystal-appoints-james-sapirstein-chief-executive-officer/) The antiviral developer names a former biopharma chief executive with 23 product launches to lead the company, effective immediately. 5. 2026-05-26 Company Updates [Cocrystal reports pan-viral inhibitors active against hantavirus and influenza](https://aibio.space/news/cocrystal-reports-pan-viral-inhibitors-active-against-hantavirus/) The company says its novel direct-acting antivirals show pan-viral activity in early in vitro work against hantavirus, bunyavirus and influenza. 6. 2026-04-30 Company Updates [Cocrystal presents CDI-988 norovirus data at ICAR 2026](https://aibio.space/news/cocrystal-presents-cdi-988-norovirus-data-icar-2026/) The company says the first cohort of its Phase 1b norovirus challenge study is fully enrolled, with prevention and treatment cohorts to follow. 7. 2026-04-02 Company Updates [FDA grants Fast Track designation to CDI-988 for norovirus](https://aibio.space/news/fda-grants-fast-track-designation-cdi-988-norovirus/) The oral antiviral candidate gains earlier FDA contact and a possible path to Priority Review, Cocrystal said in an April 2, 2026 release. 8. 2025-09-12 Financings [Cocrystal Pharma prices $4.7 million direct offering at $1.70 per share](https://aibio.space/news/cocrystal-pharma-prices-4-7-million-direct-offering-1-70-share/) The company agreed to sell 2,764,710 shares at $1.70 each, with warrants for up to 5,529,420 shares at $1.50 that could add approximately $8.3 million if fully exercised for cash. H.C. Wainwright & Co. is the placement agent. ## Cocrystal Pharma at a glance - **Ticker**: COCP - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2025**: $7.0 million ### Related companies - [Vivani Medical](https://aibio.space/companies/vivani-medical/) NASDAQ: VANI - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [Kyntra Bio](https://aibio.space/companies/kyntra-bio/) NASDAQ: KYNB - [PDS Biotechnology](https://aibio.space/companies/pds-biotechnology/) NASDAQ: PDSB - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) OTC: ACUT - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS - [Ocean Biomediacal](https://aibio.space/companies/ocean-biomediacal/) OTC: OCEA ### Also on NASDAQ - [Eocene](https://aibio.space/companies/eocene/) EOCN - [Benitec Biopharma](https://aibio.space/companies/benitec-biopharma/) BNTC - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) CARL - [Nuvectis Pharma](https://aibio.space/companies/nuvectis-pharma/) NVCT - [NEOGEN CORP](https://aibio.space/companies/neogen/) NEOG - [Dianthus Therapeutics](https://aibio.space/companies/dianthus-therapeutics/) DNTH ## What Cocrystal Pharma does Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. Its small molecule candidates inhibit the viral replication function of RNA viruses, including influenza virus, norovirus, coronaviruses (including SARS-CoV-2 and MERS-CoV), respiratory virus infections and hepatitis C virus (HCV) infections. The company uses a proprietary structure-based platform that combines computational chemistry, medicinal chemistry and X-ray crystallography. It determines the structures of cocrystals containing inhibitors bound to viral enzymes to guide drug design, and it aims for broad-spectrum candidates with a high barrier to viral resistance. Its approach was developed under the guidance of Dr. Roger Kornberg, the company's Chief Scientist and Chairman of its Scientific Advisory Board and Board of Directors, who received the Nobel Prize in Chemistry in 2006. The company describes its portfolio as including discovery, preclinical and clinical stage antiviral compounds, and it states that it operates as one business entity. | Product or program | What it is | Stage | |---|---|---| | Influenza virus antivirals | Direct-acting antivirals targeting influenza viral replication enzymes | discovery, preclinical and clinical stages (portfolio-wide) | | Norovirus antivirals | Direct-acting antivirals targeting norovirus replication | discovery, preclinical and clinical stages (portfolio-wide) | | Coronavirus antivirals | Antivirals for SARS-CoV-2 and MERS-CoV | discovery, preclinical and clinical stages (portfolio-wide) | | Hepatitis C antivirals | Antivirals for hepatitis C virus infection | discovery, preclinical and clinical stages (portfolio-wide) | | Respiratory virus antivirals | Antivirals for respiratory virus infections | discovery, preclinical and clinical stages (portfolio-wide) | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm). ## Cocrystal Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$5.1 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | [$12.5 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | | Net income (loss) | [-$8.8 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | [-$17.5 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | | Cash from operations | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | [-$16.5 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | | Cash and equivalents | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | [$9.9 million](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/) | Latest balance sheet, Dec 31, 2025 (10-K): cash and equivalents $7.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cocrystal Pharma Has Cocrystal Pharma raised money recently? Our latest story on this, dated Aug 3, 2026: "Cocrystal sells $5 million of stock to OPKO Health". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cocrystal-sells-5-million-stock-opko-health/). What is the ticker symbol of Cocrystal Pharma? Cocrystal Pharma, Inc. trades under the ticker COCP on NASDAQ. Where is Cocrystal Pharma listed? Cocrystal Pharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8CC; LS:A3DWYX. What is the SEC CIK of Cocrystal Pharma? The SEC Central Index Key (CIK) for Cocrystal Pharma, Inc. is 1412486. Its filings are on SEC EDGAR. How many shares does Cocrystal Pharma have outstanding? 19,263,200 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Cocrystal Pharma listed under? Our directory records Cocrystal Pharma, Inc. under United States. What does Cocrystal Pharma do? Our directory classifies Cocrystal Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cocrystal Pharma? The ISIN recorded for Cocrystal Pharma, Inc. is US19188J4094. Does aibio.space cover Cocrystal Pharma? aibio.space lists Cocrystal Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cocrystal Pharma incorporated? SEC records list its state or country of incorporation as DE. What does Cocrystal Pharma develop? Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. Its small molecule candidates inhibit the viral replication function of RNA viruses, including influenza virus, norovirus, coronaviruses (including SARS-CoV-2 and MERS-CoV), respiratory virus infections and hepatitis C virus (HCV) infections. What is Influenza virus antivirals from Cocrystal Pharma? Influenza virus antivirals: Direct-acting antivirals targeting influenza viral replication enzymes Stage: discovery, preclinical and clinical stages (portfolio-wide). What is Norovirus antivirals from Cocrystal Pharma? Norovirus antivirals: Direct-acting antivirals targeting norovirus replication Stage: discovery, preclinical and clinical stages (portfolio-wide). Is Cocrystal Pharma profitable? Cocrystal Pharma, Inc. reported a net loss of $8.8 million for the fiscal year ended Dec 31, 2025, and used $8.2 million of cash in operations, per its annual report to the SEC. How much does Cocrystal Pharma spend on research and development? $5.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Cocrystal Pharma Members talk about Cocrystal Pharma (COCP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cocrystal Pharma, newest first. Each line links the filing it comes from. 1. 2026-08-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/ex99-1.htm) 2. 2026-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm) 3. 2025-09-12 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1412486/000164117225027246/ex99-1.htm) 4. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:COCP on TradingView](https://www.tradingview.com/symbols/NASDAQ-COCP/). ## SEC filings and registration - **SEC name**: Cocrystal Pharma, Inc. - **CIK**: 1412486 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: COCP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 19805 N. CREEK PARKWAY, BOTHELL, WA, 98011 - **Phone**: (786) 459-1831 - **Shares outstanding**: 19,263,200 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: BIOZONE PHARMACEUTICALS, INC.; International Surf Resorts, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/form8-k.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226039023/form8-k.htm) filed 2026-08-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226038747/form8-k.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1412486/000149315226037573/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226035743/form8-k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226033662/form8-k.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/form8-k.htm) filed 2026-06-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/form8-k.htm) filed 2026-06-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001412486), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cocrystal Pharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker COCP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cocrystal Pharma, Inc. - **Ticker**: COCP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US19188J4094 - **Other listed symbols**: GETTEX:8CC; LS:A3DWYX - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-COCP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cocrystal-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cocrystal Pharma (COCP) news: offering", 2026-10-31, https://aibio.space/companies/cocrystal-pharma/